Low-dose IL-2 therapy was well tolerated and showed indications of clinical efficacy in a phase I–IIa trial of 46 patients with any one of 11 autoimmune diseases (including rheumatoid arthritis, ankylosing spondylitis, systemic lupus erythematosus and several forms of vasculitis). Patients received low-dose IL-2 (1,000,000 IU/day) for 5 days, then once every 2 weeks for 6 months. Across all diseases, regulatory T cells, but not effector T cells, were expanded and activated following treatment, indicating a potential use for low-dose IL-2 therapy across the spectrum of autoimmune diseases.
References
Original article
Rosenzwajg, M. et al. Immunological and clinical effects of low-dose interleukin-2 across 11 autoimmune diseases in a single, open clinical trial. Ann. Rheum. Dis. https://doi.org/10.1136/annrheumdis-2018-214229 (2018)
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Collison, J. Low-dose IL-2 therapy for autoimmune diseases. Nat Rev Rheumatol 15, 2 (2019). https://doi.org/10.1038/s41584-018-0142-1
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41584-018-0142-1